Antiverse is developing a revolutionary technology to predict antibody drug hits in a single day rather than in months through the traditional methods. A combination of cell-free technology and cutting-edge machine learning is used to develop a proprietary model that recognises and predicts features of antibody-antigen interaction. Ultimately, the customers, who are pharma companies and Contract Research Organisations (CROs), provide us with the sequence of the antigen and Antiverse provides the customers with the sequence of antibodies which bind the antigen with a high affinity. A pharma company and several CROs have already expressed a strong interest in using the service and will also provide support to develop the model as rapidly as possible. Antiverse’s technology will greatly speed up antibody hit discovery and thus enable the development of more, and better, antibody therapeutics against cancer, inflammation and rare diseases.
Visit the Antiverse website: